Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAROS in Men With Erectile Dysfunction
NCT01776320Phase 4
Key facts
- Status
- Withdrawn
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- Alprox
- Conditions
- erectile dysfunction (ED)
01
Overview
Phase 4, open-label, single-arm trial of Alprox in erectile dysfunction (ED). Primary endpoint: International Index of Erectile Function. Planned start Dec 2013; status: withdrawn.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
VITAROS
Vitaros (Alprostadil) 330 ug PRN transdermal topical
03
Who it enrols
Men 18 years and older with mild-to-moderate erectile dysfunction who are sexually active with a regular partner and have been currently or previously treated with other ED therapies.
04
Endpoints
Primary
International Index of Erectile Function
Secondary
Patient Satisfaction
Beyond the preview
Go deeper on NCT01776320.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01776320.